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Cytosolic pathogen- and damage-associatedmolec-
ular patterns are sensed by pattern recognition
receptors, including members of the nucleotide-
binding domain and leucine-rich repeat-containing
gene family (NLR), which cause inflammasome
assembly andcaspase-1 activation topromotematu-
ration and release of the inflammatory cytokines
interleukin-1b (IL-1b) and IL-18 and induction of
pyroptosis. However, the contribution of most of the
NLRs to innate immunity, host defense, and inflam-
masomeactivation and their specific agonists are still
unknown. Here we describe identification and char-
acterization of an NLRP7 inflammasome in human
macrophages,which is induced in response tomicro-
bial acylated lipopeptides. Activation of NLRP7 pro-
moted ASC-dependent caspase-1 activation, IL-1b
and IL-18 maturation, and restriction of intracellular
bacterial replication, but not caspase-1-independent
secretion of the proinflammatory cytokines IL-6 and
tumor necrosis factor-a. Our study therefore in-
creases our currently limited understanding of NLR
activation, inflammasome assembly, and maturation
of IL-1b and IL-18 in human macrophages.
INTRODUCTION
Pathogen infection triggers a host defense program utilizing
distinct germline-encoded pattern recognition receptors (PRRs),
which collectively mount an inflammatory host response via
production of proinflammatory cytokines and induction of pyrop-
tosis to eliminate invading pathogens. PRRs are not limited to
specifically recognizing conserved molecules on pathogens
referred to as pathogen-associated molecular patterns (PAMPs)
but also sense host-derived damage-associated molecular
patterns (DAMPs). Although engagement of some PRRs, such464 Immunity 36, 464–476, March 23, 2012 ª2012 Elsevier Inc.as TLRs and some nucleotide-binding domain and leucine-rich
repeat-containing gene family members (NLRs) containing a
caspase recruitment domain (NLRCs), lead to a transcriptional
response, activation of other NLRCs and NLRPs (NLRs contain-
ing a PYRIN domain; PYD) promote the maturation of the pro-
inflammatory cytokines interleukin-1b (IL-1b) and IL-18 in inflam-
masomes and the induction of pyroptosis in macrophages
(Khare et al., 2010; Schroder and Tschopp, 2010). The human
NLR family consists of 22 intracellular PRRs with a tripartite
domain architecture featuring a C-terminal leucine-rich region
(LRR), a central nucleotide binding NACHT domain, and an
N-terminal effector domain crucial for downstream signaling.
Inflammasomes are protein scaffolds linking PAMP and DAMP
recognition by PRRs to the activation of caspase-1-dependent
processing and release of IL-1b and IL-18 (Martinon et al.,
2002). PAMP and DAMP sensing occurs by the LRRs and results
in receptor unfolding, oligomerization, and PYD-mediated
adaptor protein binding (Faustin et al., 2007). ASC is the essential
adaptor for bridging NLRPs with caspase-1 (Srinivasula et al.,
2002; Stehlik et al., 2003), and macrophages deficient in Asc
are impaired in caspase-1 activation and maturation of IL-1b
and IL-18 (Mariathasan et al., 2004; Yamamoto et al., 2004).
Little is known about the nature of NLRP agonists. NLRP1
recognizes muramyl-dipeptide (MDP) and B. anthraces lethal
toxin (Boyden and Dietrich, 2006; Faustin et al., 2007). NLRP3
senses a variety of infectious and stress conditions by multiple
mechanisms that include potassium efflux, lysosomal damage,
and generation of reactive oxygen species (ROS) (Schroder
and Tschopp, 2010). Although the signals that activate NLRP6
are unknown, it assembles an inflammasome to control the gut
microflora (Chen et al., 2011; Elinav et al., 2011; Grenier et al.,
2002). However, the physiological function of most NLRPs and
their agonists is currently unknown.
Bacterial acylated (ac) lipopeptides (LP)signal throughTLR2and
promote IL-1b maturation and release from macrophages and
cause septic shock in mice (Aliprantis et al., 1999; Guan et al.,
2010; Takeuchi et al., 2000; Zhang et al., 1997). However, the
mechanism of acLP-induced IL-1b release is still elusive. In the
present study we identified an NLRP7-containing inflammasome
that senses microbial acLP and promotes caspase-1-dependent
Figure 1. MP Causes ASC Translocation from the
Nucleus to the Cytosol and Secretion of IL-1b
from MF
(A) THP-1 cells were treated with culture SN from HEK293
cells either negative (Ctrl, row 1) or positive for MP for
30 min (row 2) or for 16 hr (row 3), and treated with HKAL
(row 4), HKLP (row 5), or HKSA (row 6) for 6 hr.
(B) MF were either mock treated (upper row) or treated
with HKAL (lower row) for 6 hr and immunostained for ASC,
DNA, and actin.
Scale bars represent 20 mm.
(C) Mock and MP-infected THP-1 cells were separated
into nuclear (Nuc) and cytosolic (Cyt) fractions and ana-
lyzed by protein immunoblot.
(D and E) MF were treated with vehicle Ctrl or HKAL for
16 hr and (D) SN were analyzed for IL-1b (n = 3 ± SD) or (E)
TCL and concentrated SN were analyzed by protein
immunoblot.
(F–H) THP-1 cells were treated with vehicle Ctrl or HK
bacteria for 16 hr (F) or with Ctrl or MP-positive culture SN
for 24 hr (G). SN were analyzed for IL-1b as above or
analyzed for the presence ofMP (H) (OD600R 1.0 indicates
the presence of MP); n = 3 ± SD.
*p% 0.05.
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NLRP7 Activation by Acylated LipoproteinsIL-1b and IL-18 maturation in human macrophages to restrict
bacterial replication. Therefore, our study is an important con-
tribution toward a better understanding of the pathogen-derived
agonists that trigger NLR activation and inflammasome assembly
in human macrophages.
RESULTS
Mycoplasma spp. Activate Macrophage Inflammasomes
Mycoplasma spp. (MP) are intracellular pathogens that cause
macrophage activation (Sacht et al., 1998), so we testedwhetherImmunity 36, 4MP are sensed by inflammasomes. We previ-
ously described NLRP3 agonist-induced redis-
tribution of ASC from the nucleus to the cytosol
and inflammasome formation (Bryan et al.,
2009). We noticed that MP infection of human
THP-1 monocytic cells (Figure 1A) and treat-
ment of THP-1 cells (Figure 1A) and human pri-
mary macrophages (MF) (Figure 1B) with heat-
killed (HK) Acholeplasma laidlawii (HKAL) also
caused redistribution of ASC. Inflammasome
formation was also induced by HK Gram-
negative Legionella pneumophilia (HKLP) and
Gram-positive Staphylococcus aureus (HKSA)
(Figure 1A), which are sensed by NLRP3 and
NLRC4 or NLRP3, respectively, and require
ASC (Mariathasan et al., 2006; Vinzing et al.,
2008). Subcellular fractionation also revealed
nuclear and cytosolic ASC in mock-infected
cells, but only cytosolic ASC in MP-infected
cells (Figure 1C). To directly test MP for inflam-
masome activation, we treated MF with HKAL,
which caused a significant increase in IL-1b
release into culture supernatants (SN) (Fig-ure 1D), indicating that live and HK MP are sufficient to prime
MF and promote inflammasome activation. HKAL promoted
secretion of the mature IL-1b, as shown by the fact that total
cell lysates (TCLs) contained the 32 kDa precursor and the
mature 17 kDa IL-1b, but only the mature IL-1b was detected
in the culture SN (Figure 1E). Treatment of THP-1 cells with
HKAL, HKLP, and HKSA not only induced redistribution and
aggregation of ASC but also caused release of comparable
IL-1b (Figure 1F). Furthermore, infection of THP-1 cells with
MP promoted IL-1b release (Figure 1G). Infection was confirmed
with the MycoAlert assay (Figure 1H).64–476, March 23, 2012 ª2012 Elsevier Inc. 465
Figure 2. ASC and NLRP7 Are Required for HKAL- and acLP-Induced IL-1b Secretion
(A and B) THP-1shLuc, THP-1shCtr, and THP-1shASC cells were treated with vehicle Ctrl or HK bacteria (A) or with vehicle Ctrl, HKAL, or acLP (B) for 16 hr and SN
were analyzed for IL-1b (n = 3 ± SD). TCL were analyzed by protein immunoblot.
(C–F) THP-1 cells were transfected with pooled (C, D) or individual nontargeting (E, F) siRNAs (Ctrl) and siRNAs targeting NLRPs, as indicated, and treated with
HKAL for 16 hr. mRNA expression of NLRPs was analyzed by RT-PCR and b-actin control (C, E) and SN were analyzed for IL-1b as above (D, F). n = 3 ± SD.
(G and H) MFwere transfected with Ctrl or NLRP-specific siRNAs, treated with HKAL or FSL-1 for 16 hr. IL-1b in SNwas determined (n = 3 ± SD) (G) and silencing
of NLRP expression was confirmed by RT-PCR (H).
(I–K) THP-1 cells (I) or MF (J, K) were transfected with Ctrl or NLRP7 siRNAs, mock or acLP treated, transfected with dA:dT or primed with ultrapure LPS for 6 hr,
and infected with adenovirus (AdV) for 16 hr, as indicated, and analyzed for IL-1b (I, J) and IL-18 (K) release as above. n = 3 ± SD.
*p% 0.05.
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NLRP7 Activation by Acylated LipoproteinsMP and MP-Derived PAMPs Promote ASC-
and NLRP7-Dependent IL-1b Release
Maturation and release of IL-1b in BMDM is ASC dependent
(Mariathasan et al., 2004; Yamamoto et al., 2004). We therefore
investigated whether MP-induced IL-1b maturation also re-
quires ASC, by using THP-1 cells with stably silenced ASC
(THP-1shASC), scrambled (THP-1shCtrl), or luciferase-targeted
control shRNA (THP-1shLuc) (Bryan et al., 2009; Kung et al.,
2012). IL-1b release into culture SN of THP-1shASC cells
treated with HKAL, HKLP, or HKSA was impaired compared to
THP-1shLuc cells (Figure 2A). MP-induced TLR2 activation occurs466 Immunity 36, 464–476, March 23, 2012 ª2012 Elsevier Inc.via diacylated LP, such as FSL-1 (Garcia et al., 1998; Sacht et al.,
1998; Takeuchi et al., 2000). We therefore investigated the
contribution of acLP to this ASC-dependent response. Although
treatment of THP-1shCtrl cells with HKAL, FSL-1, diacylated
Pam2CSK4, and triacylated Pam3CSK4 caused IL-1b release,
it was impaired in THP-1shASC cells (Figure 2B), indicating that
microbial acLP are sufficient to cause ASC-dependent IL-1b
release, as shown for Asc-deficient BMDM (Ozo¨ren et al., 2006).
The requirement of ASC for MP- and acLP-induced IL-1b
release suggests the involvement of inflammasomes and we
hypothesized that NLRs are involved in this response in addition
Immunity
NLRP7 Activation by Acylated Lipoproteinsto TLRs. To identify this NLR, we performed an RNAi screen
focusing on the 14 human NLRPs, because of the ASC require-
ment. We tested expression of all NLRPs in resting and HKAL-
treated THP-1 cells by reverse transcriptase-polymerase chain
reaction (RT-PCR) and confirmed expression of 11 NLRPs
(NLRP1–NLRP3, NLRP5–NLRP9, NLRP11–NLRP13) in THP-1
cells, with no change in expression after HKAL treatment (data
not shown). We then silenced NLRP expression with pooled
siRNAs and silencing was achieved, as confirmed by RT-PCR
and qPCR, for all NLRPs except NLRP1 and NLRP13, which
we excluded from further experiments (Figure 2C, Figure S1A
available online, and data not shown). Only siRNAs targeting
NLRP7 consistently prevented HKAL-induced IL-1b release (Fig-
ure 2D). We also noticed reduced IL-1b release in cells with
silenced NLRP3, although it was not as potent as NLRP7 silenc-
ing. The increased inflammasome activity observed in response
to HKAL in NLRP12-silenced cells agrees with a previous report
showing an inhibitory role of NLRP12 on NF-kB activation and
IL-1b release in response to TLR agonists, including acLP
(Williams et al., 2005). We also validated individual siRNAs
targeting NLRP7. Only the two siRNAs causing efficient silenc-
ing, as determined by RT-PCR (Figure 2E) and quantitative
PCR (qPCR) (Figure S1B), blocked HKAL-induced IL-1b release
(Figure 2F), further suggesting that NLRP7 is required for MP-
mediated IL-1b release.
Microbial acLP Are Specifically Sensed by NLRP7
FSL-1 was sufficient to cause ASC-dependent IL-1b release
(Figure 2B) and we therefore hypothesized that NLRP7 should
also be required. We silenced NLRP7, NLRP3, and randomly
chosen NLRP2 and NLRP9 as controls in MF and determined
HKAL- or FSL-1-induced IL-1b release. Silencing of NLRP7,
but not NLRP2 or NLRP9, impaired HKAL- and FSL-1-induced
IL-1b release in MF (Figure 2G). Silencing of NLRP3 affected
HKAL- but not FSL-1-induced IL-1b release. NLR silencing
was confirmed by RT-PCR (Figure 2H) and qPCR (Figure S1C).
These results support a specific role of NLRP7 in the cytosolic
MP response through FSL-1 recognition. Other acLP, such as
MALP-2, Pam2CSK4, and Pam3CSK4, mediate a TLR2-medi-
ated response similar to FSL-1 (Alexopoulou et al., 2002; Guan
et al., 2010; Takeuchi et al., 2000, 2001, 2002). We therefore
investigated whether NLRP7 is selective for MP-derived LP.
Silencing of NLRP7 prevented IL-1b release in response to
MP-derived diacylated FSL-1 and MALP-2 and reduced the
response to the synthetic diacylated Pam2CSK4 and triacylated
Pam3CSK4, but did not impair IL-1b release induced by dsDNA
(dA:dT), which is recognized by absent in melanoma 2 (AIM2)
(Fernandes-Alnemri et al., 2010; Rathinam et al., 2010) and to
adenovirus (AdV), which elicits an NLRP3-mediated response
(Muruve et al., 2008) in THP-1 cells (Figure 2I) andMF (Figure 2J).
Activation of inflammasomes promotes release of IL-1b and
IL-18 and accordingly, silencing of NLRP7 also impaired
acLP-induced IL-18 release in MF (Figure 2K).
NLRP7 and NLRP3 Sense Bacteria, but Only NLRP7
Senses acLP
Activation of BMDM with bacterial RNA or HK bacteria re-
quires costimulation with exogenous ATP (Kanneganti et al.,
2007; Mariathasan et al., 2006), but we observed that exoge-nous ATP is not necessary for NLRP3 inflammasome activation
in MF. Silencing of NLRP3 in MF was sufficient to block IL-1b
release in response to E. coli total RNA, a known NLRP3 agonist
(Kanneganti et al., 2006), and NLRP3 silencing was confirmed
by RT-PCR (Figure S2A). In addition, we observed that NLRP7
also sensed HKAL and acLP in the absence of exogenous
ATP. We therefore tested the inflammasome response to HK
Gram-negative (HKLP and Porphyromonas gingivalis, HKPG)
and Gram-positive (HKSA and Listeria monocytogenes,
HKLM) bacteria, which was NLRP3 and NLRP7 dependent
in MF (Figures 3A and 3B) and THP-1 cells (Figures S2B
and S2C). Because the NLRP3-ASC complex senses various
PAMPs, we confirmed that silencing of NLRP7 did not affect
NLRP3 or ASC expression in MF by RT-PCR (Figure 3C) and
qPCR (Figure S2D). To further examine NLR specificity, we
silenced NLRP3 and NLRP7 and treated cells with FSL-1. We
had used NLRP2 as control before and used NLRP12 because
of its inhibitory effect. Although both NLRP3 and NLRP7 are
required for HK bacteria-induced IL-1b release, only silencing
of NLRP7, but not of NLRP3 or NLRP2, impaired FSL-1-induced
IL-1b release in MF (Figure 3D) and THP-1 cells (Figure S2E),
whereas NLRP12 silencing enhanced FSL-1-induced IL-1b
release.
Nlrp3-deficient BMDM show impaired caspase-1 activation
and IL-1b release in response to infection with Gram-positive
S. aureus and L. monocytogenes (Mariathasan et al., 2006),
but L. monocytogenes is also sensed by NLRC4 and AIM2 (Wu
et al., 2010). S. aureus- and L. monocytogenes-induced IL-1b
release was blunted in cells with silenced NLRP3 and also in cells
with silenced NLRP7 (Figures 3E and 3G), indicating that NLRP7
is another cytosolic PRR recognizing both bacteria by sensing
bacterial acLP. Consistent with impaired inflammasome acti-
vation, we observed an increase in intracellular bacteria in
NLRP3- and NLRP7-silenced cells at 345 min postinfection
(Figures 3F and 3H). Because bacterial counts were identical
at 75 min postinfection, NLRP3 and NLRP7 silencing did not
affect bacterial uptake. Thus, reminiscent of NLRP3, NLRP7 in-
flammasome activation contributes to the restriction of intracel-
lular growth of S. aureus and L. monocytogenes.
Activation of inflammasomes is sometimes linked to pyropto-
sis and silencing of NLRP3-impaired early time points of pyrop-
tosis (McCoy et al., 2010) of up to 2 hr postinfection of THP-1
cells with S. aureus, as determined by lactate dehydrogenase
(LDH) release and annexin V staining, but not later time points
(Figures 3I and S2F). In contrast, NLRP7 silencing did not affect
pyroptosis at any time point tested (Figures 3I and S2F), suggest-
ing that NLRP7 is involved only in cytokine release.
NLRP7 Is Required for acLP-Induced Caspase-1
Activation
HKAL- and acLP-induced IL-1b release was caspase-1 depen-
dent, as shown by the fact that zYVAD-fmk, a specific cell
permeable caspase-1 inhibitor, completely abolished it, whereas
the caspase-9 inhibitor zLEHD-fmk had no effect (Figures 4A
and S3A). In addition, NLRP7 silencing prevented FSL-1-
induced caspase-1 activation, as demonstrated by impaired
processing of caspase-1 p45 into p35 (Figure 4B). Crude lipo-
polysaccharide (cLPS) was used as a positive control. Further-
more, NLRP7 silencing prevented release of active caspase-1Immunity 36, 464–476, March 23, 2012 ª2012 Elsevier Inc. 467
Figure 3. NLRP3 and NLRP7 Recognize Intracellular Bacteria and Restrict Bacterial Replication
(A–D) MFwere transfected with Ctrl and NLRP siRNAs, mock treated or treated with HK bacteria or FSL-1 for 16 hr, as indicated, and analyzed for IL-1b (A, B, D)
(n = 3 ± SD, *p% 0.05) or analyzed by RT-PCR (C).
(E–H) MF were transfected with Ctrl, NLRP3, or NLRP7 siRNAs and left uninfected or were infected with S. aureus (S.a.) (E, F) or L. monocytogenes (L.m.) (G, H)
and analyzed for IL-1b 345 min p.i. (E, G) (n = 3 ± SD) or were lysed at 75 and 345 min p.i. and intracellular colony forming units (CFU) were determined (F, H).
Results from a representative experiment are presented as CFU/cell and the fold increase compared to control siRNA-transfected cells at 75 min p.i. is indicated.
(I) THP-1 cells were transfected with siRNAs as indicated and kept uninfected or infected with S.a. as above. SNwere analyzed at the indicated times for released
LDH and presented as percent cytotoxicity (n = 3 ± SD; *p% 0.05); n.d., not detectable.
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NLRP7 Activation by Acylated Lipoproteinsp20 into culture SN (Figure 4C), directly demonstrating that
NLRP7-mediated caspase-1 activation is required for acLP-
induced IL-1b release.
NLRP7 Is a Bona Fide Inflammasome Activator and Does
Not Affect NF-kB
acLP, LPS, and tumor necrosis factor-a (TNF-a) activate TLR
and cytokine receptor-mediated NF-kB-dependent transcription
of inflammatory cytokines, such as TNF-a and IL-6, which is
sufficient for secretion. However, release of IL-1b requires in
addition a caspase-1-dependent maturation step. To rule out
that NLRP7 silencing had a general effect on the expression of
proinflammatory cytokines, we analyzed FSL-1-induced secre-
tion of IL-6 and TNF-a, with cLPS as control, which activates
TLR2 and TLR4. To eliminate any potential autocrine IL-1b
effects, we pretreated cells with the IL-1 receptor (IL-1R) antag-468 Immunity 36, 464–476, March 23, 2012 ª2012 Elsevier Inc.onist anakinra (Taxman et al., 2006). However, contrary to the
release of IL-1b, NLRP7 silencing did not affect the release of
IL-6 and TNF-a in MF (Figures 4D and S3C) and THP-1 cells (Fig-
ure 4E and S3B), indicating that NLRP7 is not involved in the
transcriptional regulation of cytokines. Furthermore, NLRP7
silencing did not affect FSL-1-, cLPS-, or TNF-a-induced IkBa
phosphorylation and degradation in MF and THP-1 cells (Fig-
ure 4F), further ruling out NLRP7 effects on NF-kB activation.
NLRP7 and TLR2 Are Required for acLP-Induced IL-1b
Release
FSL-1 upregulates IL-1b and IL-18 transcription through a TLR-
and NF-kB-dependent mechanism. Although we achieved effi-
cient silencing of NLRP7, this did not affect IL-1b and IL-18 tran-
scription, as determined by qPCR (Figure 5A) and expression of
pro-IL-1b in MF (Figure 5B), although we achieved efficient
Figure 4. NLRP7 Mediates acLP-Induced IL-1b Release through
Caspase-1 Activation
(A) MF were pretreated with vehicle Ctrl (DMSO), zYVAD-fmk, or zLEHD-fmk
for 1 hr, treated with vehicle Ctrl, HKAL, or FSL-1 for 16 hr, and analyzed for
IL-1b release (n = 3 ± SD); *p% 0.05.
(B and C) MF were not transfected (none) or transfected with Ctrl or NLRP7
siRNAs. Samples were mock or cycloheximide (CHX) treated (to prevent
resynthesis of pro-caspase-1) and FSL-1 or cLPS activated as indicated (B) or
FSL-1 activated (C) for 6 hr. TCL (B) and SN (C) were analyzed by protein
immunoblot.
(D and E) MF (D) or THP-1 cells (E) were transfected with Ctrl or NLRP7 siRNAs
and activated with FSL-1 or cLPS for 16 hr as indicated and SN were analyzed
for IL-6 (D) and TNF-a (E) by ELISA (n = 3 ± SD). Cells were pretreated for 1 hr
with anakinra to prevent autocrine IL-1b signaling. n.d., not detectable.
(F) MF (upper panel) and THP-1 cells (lower panel) were transfected as indi-
cated and activated with FSL-1, cLPS, or TNF-a for the indicated times, and
TCL were analyzed by protein immunoblot.
Immunity
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silencing abolished FSL-1-induced transcription of IL-1b and
IL-18 (Figure 5D) and silencing was confirmed by immunoblot
(Figures 5E and S4A). As expected, silencing of either TLR2 orNLRP7 prevented FSL-1-induced IL-1b release inMF (Figure 5F)
and in THP-1 cells (Figure S4B). Because NLRP7 silencing did
not affect IL-1b transcription, we conclude that NLRP7 is not
involved in TLR2 signaling. Tlr2 and Asc are required for
host defense against L. monocytogenes through transcription
factor and caspase-1 activation, respectively (Ozo¨ren et al.,
2006). Accordingly, silencing of NLRP7 and TLR2 impaired
L. monocytogenes-induced IL-1b release in MF (Figure 5G)
and caused increased intracellular L. monocytogenes counts
(Figure 5H). Because TLR2 is also required for efficient phagocy-
tosis of L. monocytogenes (Shen et al., 2010), intracellular
bacterial counts were lower upon TLR2 silencing compared to
NLRP7 silencing, but TLR2 also controls L. monocytogenes
infection (Torres et al., 2004). Collectively, these results demon-
strate that TLR2 and NLRP7 are required for acLP-induced IL-1b
release through distinct molecular mechanisms.
NLRP7, ASC, and Caspase-1 Assemble into a High-
Molecular-Weight Complex in Response to Bacterial
Infection
ASC, caspase-1, and NLRP7 are required for acLP-induced
maturation and release of IL-1b. Therefore, we expected ASC
to be recruited to NLRP7, similar to its recruitment to NLRP3.
Coexpression of NLRP7 with ASC caused their colocalization
in aggregates, similar to NLRP3, although additional factors
might influence this interaction, because it was not as efficient
as NLRP3 (Figure 6A). NLRP7 alone localized diffusely through-
out the cytosol (data not shown), but aggregates appeared in
cells with higher NLRP7 expression (Figure 6B). Distribution
of NLRP7 was not affected in the presence or absence of
caspase-1 expression (Figure 6B, compare lower and upper
panels). However, coexpression of NLRP7 with ASC and
caspase-1 caused colocalization of all three proteins in aggre-
gates (Figure 6C), suggesting that ASC is required to bridge
NLRP7 to caspase-1. To demonstrate that NLRP7 and ASC
physically interact, we transiently transfected GFP, GFP-
NLRP7, or GFP-NLRP3 into stably ASC-expressing HEK293
cells (HEK293ASC) and immunoprecipitated ASC. ASC copurified
NLRP3 and NLRP7, but not GFP, indicating that NLRP7 can
interact with ASC (Figure 6D). As predicted, the interaction
required the PYD of NLRP7, because NLRP7DLRR but not
NLRP7DPYD was copurified with ASC (Figure 6E). HEK293 cells
lack endogenous inflammasome proteins, but restoring defined
concentrations of pro-caspase-1, pro-IL-1b, ASC, and NLRP3 is
sufficient to release IL-1b, even in the absence of agonists (Bryan
et al., 2009). To demonstrate that the NLRP7 complex contains
inflammasome activity, we first purified NLRP7 from stable
inflammasome-reconstituted cells expressing pro-caspase-1
and ASC, transfected with NLRP7, by using immobilized
NLRP7 antibodies and control IgG. NLRP7 specifically copuri-
fied ASC and caspase-1, further indicating that all three proteins
existed in a complex (Figure 6F). We then subjected the purified
NLRP7 protein complexes, which were isolated from these cells
and from inflammasome-reconstituted cells lacking NLRP7, to
an in vitro caspase-1 activity assay. Caspase-1 activity was
copurified only from cells expressing NLRP7, indicating that an
active caspase-1 is present in the NLRP7 protein complex (Fig-
ure 6G). To further demonstrate that it has IL-1b converting
enzyme (ICE) activity, we incubated the purified NLRP7 proteinImmunity 36, 464–476, March 23, 2012 ª2012 Elsevier Inc. 469
Figure 5. NLRP7 and TLR2 Are Required for acLP-Induced IL-1b
Release
(A) MF were transfected with Ctrl or NLRP7 siRNAs, activated with FSL-1 for
16 hr, and analyzed by qPCR (relative expression compared to b-actin, n =
3 ± SD). Silencing efficiency is indicated in percentage compared to control
siRNA.
(B) MF were transfected with Ctrl or NLRP7 siRNAs and activated with FSL-1
for 16 hr in the presence of zYVAD-fmk to prevent maturation of IL-1b, and TCL
were analyzed for pro-IL-1b by protein immunoblot.
(C) THP-1 cells were transfected with Ctrl or NLRP7 siRNAs and analyzed
by protein immunoblot, with NLRP7-transfected HEK293NLRP7 cells as control.
(D) THP-1 cells were transfected with Ctrl or TLR2 siRNAs, treated with FSL-1
for 16 hr, and analyzed by qPCR for IL-1b and IL-18 mRNA, as described
above. n = 3 ± SD.
(E and F) MF were transfected with Ctrl, NLRP7, or TLR2 siRNAs, mock
treated or treated with FSL-1 for 16 hr. TCL were analyzed by protein
immunoblot with TLR2-transfected HEK293TLR2 cells as control (E). Asterisk
indicates cross-reactive protein. TCL were analyzed for IL-1b release (F)
(n = 3 ± SD).
Immunity
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470 Immunity 36, 464–476, March 23, 2012 ª2012 Elsevier Inc.complexes with a protein lysate containing pro-IL-1b as a
substrate. Only the NLRP7 protein complex purified from cells
expressing NLRP7 contained ICE activity, as determined by its
capability to mature pro-IL-1b (Figure 6H).
We then investigated endogenous NLRP7 inflammasome
formation by size exclusion chromatography (SEC) of TCL (Fig-
ure S5). Although NLRP7 was present in fractions corresponding
to its molecular weight in resting cells, it was efficiently shifted
into a high-molecular-weight (HMW) complex after S. aureus
infection of MF (Figure 6I). This complex was less than 1.5
MDa, as shown by the fact that NLRP7 was not present in the
void volume (first fraction). Also, ASC and caspase-1 shifted
into the NLRP7-containing HMW fractions in S. aureus-infected
MF. Caspase-1 copurified ASC and NLRP7 from the HMW
(fractions 2–6) but copurified only ASC from the low-molecular-
weight (LMW) (fractions 19–24) after S. aureus infection (Fig-
ure 6J). We also performed the reciprocal experiment and
purified NLRP7 from both fractions, and caspase-1 activity
was purified only from the HMW fraction (Figure 6K), which
also contained ICE activity (Figure 6L), providing biochemical
support for NLRP7-containing inflammasome formation.
NLRP7, ASC, and Caspase-1 Are Sufficient for the
Inflammasome Response to MP and acLP
We used the inflammasome reconstitution system to dissect
NLRP7 signaling. NLRP7 expression alone was not sufficient
to cause IL-1b release in the presence of pro-caspase-1 but
required coexpression of ASC (Figure 7A), further emphasizing
the essential role of ASC in the NLRP7 inflammasome. To
directly demonstrate that NLRP7 is sufficient for HKAL and
FSL-1 recognition, we transfected cells with suboptimal concen-
trations of NLRP7, followed by a second transfection to deliver
HKAL and FSL-1 to the cytosol. Although transfection of HKAL
and FSL-1 did not promote IL-1b release in control cells, it
enhanced IL-1b release in NLRP7-transfected cells (Figure 7B).
Addition of HKAL or FSL-1 to the culture medium also caused in-
flammasome activity, albeit less than the activity obtained by
cytosolic delivery of HKAL or FSL-1 (Figure S6A), because
agonists need to reach the cytosol for NLR activation. To demon-
strate the specificity of acLP for NLRP7, we reconstituted NLRP7
and NLRP3 inflammasomes and used Nod1, which can directly
interact with caspase-1 (Yoo et al., 2002), and the inflamma-
some-unrelated AFAP1 as controls. FSL-1 caused significantly
increased IL-1b release only in reconstituted NLRP7 inflamma-
somes (Figure 7C). As expected, AFAP1 did not promote IL-1b
maturation. It is generally believed that the LRR is required for
ligand sensing and specificity, and deletion of the LRR renders
NLRP3 unresponsive in vivo (Hoffman et al., 2010). However,
previous studies demonstrate that deletion of the LRR in several
NLRs renders the protein hyperactive in vitro. NLRP7DLRR
similarly displayed enhanced activity in the inflammasome(G and H) MF were transfected with Ctrl, NLRP7, or TLR2 siRNAs and either
left uninfected or were infected with L. monocytogenes (L.m.) and were
analyzed for IL-1b release 345 min p.i. (G), or were lysed at 75 and 345 min p.i.
(H) and CFU were determined. Results are presented as CFU/cell and the fold
increase compared to Ctrl siRNA-transfected cells at 75 min p.i. is indicated
(n = 3 ± SD).
n.d., not detectable; *p% 0.05.
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Collectively, these experiments demonstrate that NLRP7 is suffi-
cient to promote FSL-1-induced inflammasome activation and
that the LRR is necessary to sense acLP.
We next started to investigate the mechanism of NLRP7 acti-
vation. Hereditary mutations within the NACHT-LRR region of
NLRP3 cause excessive release of IL-1b through constitutive in-
flammasome activation. Several hereditary mutations have also
been identified in NLRP7 and are linked to recurrent hydatidiform
moles (HM), but a link to IL-1b or IL-18 is not known (Murdoch
et al., 2006). Comparison of WT and three HM-linked NLRP7
mutations (R693W, R693P, and D657V) in the inflammasome
reconstitution assay provided evidence that HM-linked muta-
tions are more potent in activating inflammasomes than NLRP7
in vitro (Figure 7E).
Direct interaction of any ligand with an NLRP has not been
demonstrated, but several indirect mechanism have been pro-
posed for NLRP3 activation, including lysosomal damage,
cathepsin B release, ROS generation, and K+ efflux (Schroder
and Tschopp, 2010). We could not detect colocalization of fluo-
rescently labeled FSL-1 with NLRP7, nor could we copurify bio-
tinylated FSL-1 with NLRP7 (data not shown), suggesting an
indirect mechanism of NLRP7 activation, as proposed for
NLRP3. Lysosomal destabilization with the dipeptide Leu-Leu-
OMe resulted in IL-1b release in MF, which was significantly
blocked upon silencing of NLRP3 and NLRP7 (Figure 7F), sug-
gesting that both function downstream of lysosomal damage.
Lysosomal rupture releases cathepsin B, which promotes
NLRP3 activation in response to particulates (Hornung et al.,
2008). Although MSU crystal-induced NLRP3 activation was
blocked in cells treated with the cathepsin B inhibitor CA-074-
Me (Figure 7G), FSL-1-induced IL-1b release was only partially
prevented, suggesting mechanistic differences of NLRP3 and
NLRP7 activation (Figure 7H). A distinct activation mechanism
is also supported by the observation that MSU-induced NLRP3
activation was impaired when cells were cultured in 130 mM
KCl-containing medium (Figure 7G), which blocks K+ efflux
(Pe´trilli et al., 2007), but FSL-1-induced IL-1b release was only
slightly affected (Figure 7H). The ROS scavenger NAC and the
NADPH oxidase inhibitor APDC prevent MSU-induced IL-1b
release (Dostert et al., 2008), but we did not observe any effect
(data not shown), which is not surprising considering that
NLRP7 activation is independent of K+ efflux, which is frequently
linked to ROS generation.
DISCUSSION
Our study in MF identified the NLRP7 inflammasome, which
sensed microbial infection through recognition of acLP. An
earlier study failed to detect IL-1b release by immunoblot in
response to the acLP Pam3Cys after only 3 hr of activation
(Martinon et al., 2004). The use of a more sensitive ELISA assay
and increased activation time allowed us to detect acLP-induced
IL-1b release, in agreement with Nlrp3-independent acLP-
induced IL-1b secretion (Kanneganti et al., 2006). NLRP3 is acti-
vated by diverse stimuli, including phagocytosis of bacteria, and
silencing of NLRP3 or NLRP7 inhibited the response to HK and
live bacteria, but only silencing of NLRP7 impaired the acLP-
induced response. We propose that NLRP7 specifically re-cognizes bacterial acLP. Our results indicate that NLRP7 is an
inflammasome activator and not a signaling component down-
stream of TLR2. Nevertheless, an initial extracellular acLP-
induced transcriptional response through TLR2 is required for
NF-kB-dependent IL-1b and IL-18 transcription (Aliprantis
et al., 1999; Guan et al., 2010; Takeuchi et al., 2000). Accord-
ingly, silencing of TLR2 impaired IL-1b transcription and release,
but caspase-1 activation is not impaired in MF of Tlr2-, Tlr4-,
MyD88-, and Trif-deficient mice, clearly separating it from TLR
signaling (Kanneganti et al., 2007), and we ruled out effects on
cytokine transcription. Furthermore, in our inflammasome recon-
stitution assay, synthesis of IL-1bwas TLR2 and NF-kB indepen-
dent, as shown by the fact that HEK293 cells lack TLR2. Col-
lectively, our results indicate that TLR2 signaling is necessary
for IL-1b and IL-18 transcription, whereas NLRP7 is essential
for IL-1b and IL-18 maturation and release in response to
acLP. In contrast, a previous in vitro study suggested that
NLRP7 is an inhibitor of caspase-1, based on the stable expres-
sion of a truncated NLRP7 in THP-1 cells (Kinoshita et al., 2005).
A HEK293 cell overexpression study suggested that NLRP7
negatively regulates expression of cotransfected pro-IL-1b
(Messaed et al., 2011a), whereas another study in HEK293 cells
did not observe effects on IL-1b secretion (Grenier et al., 2002).
In contrast, we showed that endogenous NLRP7 forms an
ASC-dependent inflammasome in response to acLP in MF.
Insufficient sensitivity may prevent detecting the NLRP7 inflam-
masome, as indicated by our observation that overexpressed
NLRP7 is unstable and proteasomally degraded, resulting in
lower expression compared to other NLRs. In addition, NLRs
are spliced, resulting in altered activities. NLRP7 in our study
contained nine LRRs (118 kDa), but we also cloned a shorter
transcript (NLRP7-S; 109 kDa) with five LRRs and reduced
activity (Figure S6B).
Differences exist in the repertoire of human and mouse NLRs
andNlrp7 is lacking frommice, but nevertheless, one can expect
the existence of an acLP-sensing functional NLRP7 mouse
analog. Another difference is that BMDM require exogenous
ATP for IL-1b release, whereas MF release IL-1b in response
to acLP alone. Future studies will need to identify themechanism
of NLRP7 activation and address whether the agonist repertoire
of NLRP7 is similar to that of TLR2 (i.e., restricted to acLP) or
whether it responds to non-TLR2 agonists also. acLP are used
as vaccine adjuvant and immune-activating serum acLP have
been identified (Thacker et al., 2009). Thus, NLRP7-activating
DAMPs might exist, similar to the ones recognized by NLRP3.
Hereditarymutations in NLRP7 are linked to HM,which predis-
poses women toward molar pregnancy and may develop into a
choriocarcinoma, but only 60% of HM patients harbor NLRP7
mutations (Murdoch et al., 2006). It is not known whether IL-1b
or IL-18 contribute to HM (Slim and Mehio, 2007). Monocytes
from some HM patients with NLRP7 mutations show reduced
IL-1b secretion (Messaed et al., 2011a), whereas two out of
four HM patients showed increased IL-1b secretion in another
study (Messaed et al., 2011b), but even the general population
show varying IL-1b secretion (Gattorno et al., 2007). Our prelim-
inary results from three common HM mutations showed in-
creased activity in the inflammasome reconstitution system,
but future studies need to investigate the contribution of IL-1b
and IL-18 to HM. In addition, a connection among latent MPImmunity 36, 464–476, March 23, 2012 ª2012 Elsevier Inc. 471
Figure 6. Activation of NLRP7 Causes the Formation of a High-Molecular-Weight Inflammasome in MF
(A–C) Immunofluorescence staining of HEK293 cells transiently transfected with ASC and NLRP3 (upper row), ASC and NLRP7 (bottom panel) (A), NLRP7 and
pro-caspase-1 (upper row shows a cell expressing only NLRP7; lower row shows cells expressing NLRP7 and caspase-1) (B), or NLRP7, ASC, and pro-
caspase-1 (C). NLR-containing aggregates are marked by arrowheads. Scale bars represent 20 mm.
(D) HEK293ASC cells were transfected with GFP, GFP-NLRP3, or GFP-NLRP7 as indicated and TCLwere used for IP with immobilized myc antibodies and protein
immunoblot as indicated.
(E) HEK293 cells were transfected with HA-ASC, myc-NLRP7DLRR, or myc-NLRP7DPYD, as indicated, and TCL were used for IP with immobilized HA antibodies
and protein immunoblot as indicated.
(F–H) Stable HEK293 inflammasome-reconstituted cells (HEK293Inflammasome) were transfected with control or NLRP7 as indicated, and TCLwere used for IP with
immobilized NLRP7 antibodies. Immune complexes were analyzed by protein immunoblot as indicated (F) or equilibrated in caspase-1 assay buffer and sub-
jected to in vitro caspase-1 activity assay (G) or for ICE activity incubated with a TCL isolated from HEK293 cells transfected with pro-IL-1b and analyzed by
protein immunoblot for mature IL-1b (H).
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Figure 7. Reconstituted NLRP7 Inflammasomes Are Sufficient to Respond to HKAL and acLP
(A) HEK293 cells were transiently transfected as indicated and release of IL-1b was determined in SN. Results are presented as fold increase compared to cells
transfected with pro-IL-1b and pro-caspase-1 (n = 3 ± SD); *p% 0.05 compared to cells not transfected with NLRPs.
(B) HEK293 cells were transfected as above with suboptimal concentrations of NLRP7, followed by a second transfection after 24 hr with transfection reagent
alone (Ctrl), HKAL (8 3 105 cfu), or FSL-1 (0.5 mg). Secreted IL-1b is presented as fold increase compared to control transfected cells (n = 3 ± SD); *p% 0.05
compared to cells lacking NLRP7; **p% 0.05 compared to the second round of mock transfected cells.
(C) HEK293 cells were transfected as above with suboptimal concentrations of NLRP7, NLRP3, Nod1, or AFAP1, followed by FSL-1 transfection. Secreted IL-1b
is presented as fold increase compared to Ctrl transfected cells (n = 3 ± SD); *p% 0.05 compared to cells lacking NLRs; **p% 0.05 compared to the second round
of mock transfected cells. Expression of NLRP7 (118 kDa), NLRP3 (118 kDa), Nod1 (107 kDa), and AFAP1 (110 kDa) in the inflammasome reconstitution assay
was verified by protein immunoblot.
(D) HEK293 cells were transfected and analyzed for IL-1b secretion as above, but with NLRP7 and NLRP7DLRR (n = 3 ± SD); *p% 0.05 compared to the second
round of mock transfected cells.
(E) HEK293 cells were transfected with NLRP7, NLRP7R693W, NLRP7R693P, or NLRP7D657V, followed by FSL-1 transfection as above and secreted IL-1b is
presented as fold increase compared to cells transfected with pro-IL-1b and pro-caspase-1 (n = 3 ± SD); *p% 0.05 compared to cells not transfected with FSL-1;
**p% 0.05 compared to cells transfected with NLRP7; ***p% 0.05 compared to cells transfected with NLRP7 and FSL-1. Expression of NLRP7 was verified by
protein immunoblot.
(F) MFwere transfected with Ctrl, NLRP3, or NLRP7 siRNAs, primed with ultrapure LPS for 4 hr, and either left untreated or lysosomal damage was inflicted with
Leu-Leu-OMe for 16 hr and analyzed for IL-1b release (n = 6 ± SD).
(G andH) THP-1 cells were pretreatedwith either medium containing 130mMKCl (KCL) or a cathepsin B inhibitor (CA-074-Me), mock treated or treatedwithMSU
(G) or FSL-1 (H) for 8 hr and secreted IL-1b was determined (n = 3 ± SD); *p% 0.05.
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will need to be elucidated. Inhibition of bacterial replication is
independently achieved by autocrine IL-1b signaling and pyrop-
tosis (Broz et al., 2010), but we did not observe NLRP7-mediated
pyroptosis, indicating that NLRP7 acts through cytokine release
to limit bacterial replication, supported by the critical role of IL-1b(I–L) Ctrl or S.a.-infected MF were fractionated by SEC and pooled fractions
caspase-1 was immunoprecipitated from fractions 2–6 and 19–24 of S.a.-infecte
NLRP7 was immunoprecipitated from the same fractions (K, L) and assayed for ca
(K) or assayed for ICE activity as above (L). Asterisk indicates cross-reactive proin the host defense againstS. aureus (Bernthal et al., 2011). Thus,
our finding of NLRP7 as an activator of caspase-1, which re-
stricts intracellular bacterial replication, has broad implications
for understanding host defense and inflammatory and autoim-
mune disease and expands our limited understanding of NLRs
and their respective agonists.were TCA precipitated and analyzed by protein immunoblot as indicated (I);
d MF with IgG as control and analyzed by protein immunoblot as indicated (J);
spase-1 activity assay (activity purified from fractions 2–6 saturated the assay)
tein.
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Materials and Cell Culture
THP-1 cells and MF were treated with HK Acholeplasma laidlawii (HKAL),
Legionella pneumophila (HKLP), Staphylococcus aureus (HKSA), Porphyro-
monas gingivalis (HKPG), Listeria monocytogenes (HKLM) (2 3 105 cfu/ml),
FSL-1 (0.1 mg/ml), Pam2CSK4 (2 mg/ml), Pam3CSK4 (2 mg/ml), ultrapure LPS
(10 ng/ml, Invivogen), crude E. coli LPS (cLPS, 0111:B4, 600 ng/ml, Sigma),
MALP-2 (0.2 mg/ml, Imgenex), TNF-a (20 ng/ml, Biosource), or Leu-Leu-OMe
(1 mM; Bachem) or cells were transfected with dA:dT (2 ng/ml, Sigma) with lip-
ofectamine LTX+ (Invitrogen) or infected with adenovirus (AdV, serotype 5).
Where indicated, cellswerepretreated for 1hrwithAnakinra (10mg/ml, Amgen),
zYVAD-fmk or zLEHD-fmk (100 mM, Calbiochem), CA-074-Me (50 mM), or with
medium containing 130 mM KCl. Stable THP-1shASC, THP-1shLuc, and
THP-1shCtrl cells were described previously (Bryan et al., 2009; Kung et al.,
2012). Blood from healthy donors was drawn after obtaining informed consent
under a protocol approved by NU Institutional Review Board.
Bacterial Infection
THP-1 cells were treated with culture SN from HEK293 cells that tested nega-
tive or positive for MP, as determined by morphology, DAPI staining, and MP
test (MycoAlert, Lonza). Control HEK293 cells were grown in the presence of
Plasmocin and Plasmocure (Invivogen) to prevent MP infection. At 67 hr post-
transfection, cells were infected with Listeria monocytogenes (MOI = 12) or
Staphylococcus aureus (MOI = 3) for 45 min. Extracellular bacteria were elim-
inated with gentamycin (50 mg/ml) for 30 min, followed by collection of culture
SN for ELISA as indicated and lysed in 0.02% Triton X-100 for CFU
determination.
Immunofluorescence Microscopy
Cells were fixed, permeabilized, and immunostained as described (Bryan
et al., 2009). For colocalization studies, HEK293 cells were transfected with
NLRP7 or cotransfected with ASC and/or pro-caspase-1. Images were
acquired by confocal laser scanning and epifluorescence microscopy on
a Zeiss LSM 510 and a Nikon TE2000E2-PFS with a 1003 oil objective and
image deconvolution.
Subcellular Fractionation
106 cells were fractionated by hypotonic lysis and centrifugation into cytosolic
and nuclear fractions as previously described (Bryan et al., 2009).
Cytokine and Caspase-1 Measurement
Cytokine secretion was quantified from clarified culture SN by ELISA (BD
Biosciences, Invitrogen) from 33 105 MF after treatment for 5 hr (live bacteria)
or 16 hr (all other treatments), or 24 hr posttransfection of 4 3 105 HEK293
cells. Samples were analyzed in triplicate and repeated at least three
times, showing a representative result. TCL (3 3 105 MF) and SN (4 3
106 MF) were analyzed for caspase-1 by protein immunoblot. Cycloheximide
(10 mg/ml) was added to prevent resynthesis of pro-caspase-1 when analyzing
TCL. In vitro caspase-1 activity was determined by kinetic fluorescence assay
with NLRP7 immune complexes isolated from 5–12 3 107 S. aureus-infected
and size fractionated MF, or from HEK293Inflammasome cells transfected with
control or NLRP7 in assay buffer (50 mM HEPES [pH 7.4], 50 mM NaCl,
1 mM EDTA, 0.1% Chaps, 10% sucrose, 10 mM DTT, 50 mM AcYVAD-AFC),
and fluorescence was determined at 37C at 400/505 nm. Caspase-1 proteo-
lytic activity was determined by incubating NLRP7 complexes in assay buffer,
supplemented with TCL from HEK293 cells transfected with pro-IL-1b, and
analysis of mature IL-1b by protein immunoblot.
Pyroptosis
Lactate dehydrogenase (LDH) activity was measured with a kit (Clontech).
Cells were lysed with 1% Triton X-100 for maximal LDH release.
Inflammasome Reconstitution System
HEK293 cells were transfected with expression constructs for mouse
pro-IL-1b and human pro-caspase-1, ASC, and NLRs by Lipofectamine
2000 (Invitrogen). A stably transfected HEK293 reconstitution system
(HEK293Inflammasome) was used in some experiments. Cells were transfected474 Immunity 36, 464–476, March 23, 2012 ª2012 Elsevier Inc.a second time with transfection mixture, HKAL (8 3 105 cfu), or FSL-1
(500 ng) with Lipofectamine 2000.
Coimmunoprecipitation
Stable myc-ASC HEK293 cells (HEK293ASC) were transfected with GFP,
GFP-NLRP3, or GFP-NLRP7, adjusted to yield comparable expression. Alter-
natively, HEK293 cells were transfected with HA-ASC and myc-NLRP7DLRR or
NLRP7DPYD, or HEK293Inflammasome cells were transfected with control or
NLRP7. Cells were lysed (120 mM NaCl, 20 mM Tris [pH 7.4], 10% glycerol,
0.2% Triton X-100, and protease inhibitors) 36 hr posttransfection. Cleared
TCL or SEC fractions were subjected to IP with immobilized antibodies as indi-
cated for 12 hr at 4C and washed in lysis buffer, and bound proteins were
analyzed by protein immunoblot with HRP-conjugated secondary native
IgG-recognizing antibodies (eBioscience), ECL detection (Pierce), and image
acquisition (Ultralum). TCL (10% volume) were analyzed where indicated.
Size Exclusion Chromatography
TCL were prepared from 5–123 107 Ctrl and 90 min S. aureus-infected MF by
lysis in SEC buffer (10 mM Na4P2O7, 10 mM NaF, 5 mM Tris [pH 7.4], 150 mM
NaCl, 1% octylglucoside, and protease inhibitors) for 5 min on ice and Dounce
homogenization. TCL were cleared by centrifugation (12,000 3 g at 4C for
30 min) and 0.45 mm filtration. SEC was performed on a 16 3 600 mm HiPrep
Sephacryl S300HR column (GE Healthcare) in 50 mM Tris (pH 7.4), 150 mM
NaCl at 4C at a flow rate of 0.5 ml/min. Collected fractions were either TCA
precipitated for protein immunoblot analysis or used to purify protein
complexes.
siRNA Transfection
3 3 105 THP-1 cells were electroporated (Invitrogen) with 60 nM single or
pooled siRNA duplexes and MF were transfected with 120 nM siRNA (F2/
virofect; Targeting Systems) and analyzed 72 hr posttransfection.
RNA Isolation and RT-PCR
Total RNA was isolated (Trizol, Invitrogen), DNase I digested, reverse tran-
scribed (Superscript III, Invitrogen), and analyzed by exon-spanning RT-PCR
(Table S2) or qPCR (Applied Biosystems) and displayed as relative expression
compared to b-actin. PCR products were sequence verified.
Statistics
A standard two-tailed t test was used for statistical analysis and values of p%
0.05 were considered significant.
SUPPLEMENTAL INFORMATION
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